keyword
https://read.qxmd.com/read/38473297/clinical-benefit-from-docetaxel-ramucirumab-is-not-associated-with-mutation-status-in-metastatic-non-small-cell-lung-cancer-patients-who-progressed-on-platinum-doublets-and-immunotherapy
#21
JOURNAL ARTICLE
Kang Qin, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M Hubert, Xiuning Le, Natalie Vokes, Kunal Rai, Ara Vaporciyan, Don L Gibbons, John V Heymach, J Jack Lee, Scott E Woodman, Caroline Chung, David A Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang
Docetaxel +/- ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/- ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/- ramucirumab n=381; platinum/taxane-based regimens n=73)...
February 26, 2024: Cancers
https://read.qxmd.com/read/38469817/genome-wide-analysis-identified-sema4d-novel-candidate-gene-for-temperature-sensitivity-in-patients-with-non-small-cell-lung-cancer
#22
JOURNAL ARTICLE
Jung-Hyang Park, Eunbin Kwag, Mi-Kyung Jeong, So-Jung Park, Sanghun Lee, Hwa-Seung Yoo
BACKGROUND: In the era of precision medicine, individual temperature sensitivity has been highlighted. This trait has traditionally been used for cold-heat pattern identification to understand the inherent physical characteristics, which are influenced by genetic factors, of an individual. However, genome-wide association studies (GWASs) on this trait are limited. METHODS: Using genotype data from 90 patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations, we performed a GWAS to assess the association between single nucleotide polymorphisms (SNPs) and temperature sensitivity, such as cold and heat scores...
2024: Integrative Cancer Therapies
https://read.qxmd.com/read/38464122/machine-learning-identifies-cell-free-dna-5-hydroxymethylation-biomarkers-that-detect-occult-colorectal-cancer-in-plco-screening-trial-subjects
#23
Diana C West-Szymanski, Zhou Zhang, Xiao-Long Cui, Krissana Kowitwanich, Lu Gao, Zifeng Deng, Urszula Dougherty, Craig Williams, Shannon Merkle, Matthew Moore, Chuan He, Marc Bissonnette, Wei Zhang
BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer-related mortality, and CRC detection through screening improves survival rates. A promising avenue to improve patient screening compliance is the development of minimally-invasive liquid biopsy assays that target CRC biomarkers on circulating cell-free DNA (cfDNA) in peripheral plasma. In this report, we identify cfDNA biomarker candidate genes bearing the epigenetic mark 5-hydroxymethylcytosine (5hmC) that diagnose occult CRC up to 36 months prior to clinical diagnosis using the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial samples...
February 26, 2024: bioRxiv
https://read.qxmd.com/read/38445462/methylation-status-of-mir-34a-and-mir-126-in-non-small-cell-lung-cancer-nsclc-tumor-tissues
#24
JOURNAL ARTICLE
Nazanin Mehrzad, Mohammad Saber Zamani, Amirabbas Rahimi, Masoud Shamaei, Morteza Karimipoor
BACKGROUND: Non-small cell lung cancer accounts for 85% of tumors of the lung and is a leading cause of cancer mortality worldwide. MiR-34a and miR-126 mainly act as tumor suppressors and are often downregulated in various cancers, including NSCLC. METHODS: The current study included 63 paraffin-embedded NSCLC and paired adjacent normal tissues. After DNA extraction and bisulfite treatment, the methylation status of miR-34a and miR-126 were evaluated using the MSP method...
September 3, 2023: Iranian Biomedical Journal
https://read.qxmd.com/read/38443832/loss-of-chromosome-y-in-regulatory-t-cells
#25
JOURNAL ARTICLE
Jonas Mattisson, Jonatan Halvardson, Hanna Davies, Bożena Bruhn-Olszewska, Paweł Olszewski, Marcus Danielsson, Josefin Bjurling, Amanda Lindberg, Ammar Zaghlool, Edyta Rychlicka-Buniowska, Jan P Dumanski, Lars A Forsberg
BACKGROUND: Mosaic loss of chromosome Y (LOY) in leukocytes is the most prevalent somatic aneuploidy in aging humans. Men with LOY have increased risks of all-cause mortality and the major causes of death, including many forms of cancer. It has been suggested that the association between LOY and disease risk depends on what type of leukocyte is affected with Y loss, with prostate cancer patients showing higher levels of LOY in CD4 + T lymphocytes. In previous studies, Y loss has however been observed at relatively low levels in this cell type...
March 5, 2024: BMC Genomics
https://read.qxmd.com/read/38434971/exploration-of-radiotherapy-strategy-for-brain-metastasis-patients-with-driver-gene-positivity-in-lung-cancer
#26
JOURNAL ARTICLE
Qian Bi, Xin Lian, Jing Shen, Fuquan Zhang, Tao Xu
Objective: To assess the disparities in effectiveness and identify outcome predictors in the treatment of a targeted-first and radiotherapy-first regimen with driver gene-positive lung cancer brain metastases. Materials and Methods: This retrospective study analyzed patients with driver gene-positive lung cancer brain metastases who received first-targeted and first-radiotherapy regimens, respectively, with SIB-WBRT (whole brain tissue 40 Gy/20 fractions, tumor tissue boosted to 56-60 Gy/20 fractions) and local irradiation (prescription dose range of 20-60 Gy/2-25 fractions, most commonly delivered as 30 Gy/5 fractions, with a BED range of 28-100...
2024: Journal of Cancer
https://read.qxmd.com/read/38433052/-intraductal-carcinomas-of-the-salivary-glands-a-clinicopathological-and-molecular-genetic-analysis-of-twenty-seven-cases
#27
JOURNAL ARTICLE
Q Sun, J J Sun, M Wang, L Zhang, X W Zhang, J G Wei, L F Kong, J Li
Objective: To investigate the clinicopathological features, molecular genetic features, and differential diagnosis of intraductal carcinomas (IDC) of the salivary glands. Methods: Twenty-five cases of salivary gland IDC diagnosed at the Department of Oral Pathology, Shanghai Ninth People's Hospital and two cases from Department of Pathology, Henan Provincial People's Hospital, Zhengzhou, China from January 2008 to July 2023 were collected. Their clinical and pathological features were analyzed retrospectively...
March 8, 2024: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://read.qxmd.com/read/38430689/exploring-the-molecular-and-immune-landscape-of-lung-cancer-associated-with-cystic-airspaces
#28
JOURNAL ARTICLE
Xiang Zheng, Li Qiu, Ying Huang, Ran Cheng, Sihe Huang, Ke Xu, Weipeng Cai, Yu Deng, Wei Wang, Xi Zhong, Fei Cui, Zhexue Hao, Jun Liu
To explore the molecular biological characteristics of lung cancer associated with cystic airspaces (LCCA) and its potential roles on prognosis. A total of 165 LCCAs and 201 non-LCCAs were enrolled in this study. Bulk RNA sequencing was implemented in eight LCCAs and nine non-LCCAs to explore the differentially expressed genes. TCGA data were used to analyze LCCA-specific genes that associated with overall survival (OS). The median age was 60 (IQR 53 to 65) years in LCCA cohort. We found LCCA were predominant in men and had less visceral pleura invasion (VPI) or lympho-vascular invasion (LVI)...
March 1, 2024: Molecular Immunology
https://read.qxmd.com/read/38421462/primary-pulmonary-myxoid-sarcoma-with-ewsr1-creb1-fusion-a-literature-review
#29
REVIEW
Xinyu Miao, Jing Chen, Lan Yang, Hongyang Lu
PURPOSE: This review primarily aims to review the epidemiology, clinical characteristics, imaging, pathology, immunohistochemistry, diagnosis, differential diagnosis, treatment, and prognosis of Primary pulmonary myxoid sarcoma (PPMS) with EWS RNA binding protein 1::cAMP response element binding protein 1 (EWSR1::CREB1) fusion. It provides reference for the diagnosis and treatment of this disease. METHODS: Retrospectively collected the literature about PPMS with EWSR1::CREB1 fusion, its clinical, radiology, histology, molecular characteristics and current treatment strategies were collated and analyzed...
February 29, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38420798/the-role-of-cd8a-in-the-immune-microenvironment-of-breast-cancer
#30
JOURNAL ARTICLE
Jian Chu, Shan Tang, Tangya Li, Huiwen Fan
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer (BC), and it is often associated with a high tumor grade, a younger age at diagnosis, and a low survival rate. Conventional endocrine and anti-HER-2 therapies are usually ineffective against TNBC, creating treatment challenges and resulting in a poor prognosis. Hence, new targets and treatment strategies for TNBC are urgently required. METHODS: The GSE102818 dataset was used to identify differentially expressed genes (DEGs) between primary BC and metastatic BC lesions...
February 21, 2024: Frontiers in Bioscience (Landmark Edition)
https://read.qxmd.com/read/38412388/cancer-risks-associated-with-tp53-pathogenic-variants-maximum-likelihood-analysis-of-extended-pedigrees-for-diagnosis-of-first-cancers-beyond-the-li-fraumeni-syndrome-spectrum
#31
MULTICENTER STUDY
Cristina Fortuno, Bing-Jian Feng, Courtney Carroll, Giovanni Innella, Wendy Kohlmann, Conxi Lázaro, Joan Brunet, Lidia Feliubadaló, Silvia Iglesias, Mireia Menéndez, Alex Teulé, Mandy L Ballinger, David M Thomas, Ainsley Campbell, Mike Field, Marion Harris, Judy Kirk, Nicholas Pachter, Nicola Poplawski, Rachel Susman, Kathy Tucker, Mathew Wallis, Rachel Williams, Elisa Cops, David Goldgar, Paul A James, Amanda B Spurdle
PURPOSE: Establishing accurate age-related penetrance figures for the broad range of cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 gene is essential to determine the most effective clinical management strategies. These figures also permit optimal use of cosegregation data for classification of TP53 variants of unknown significance. Penetrance estimation can easily be affected by bias from ascertainment criteria, an issue not commonly addressed by previous studies...
February 2024: JCO Precision Oncology
https://read.qxmd.com/read/38402182/emerging-trends-in-the-coexistence-of-primary-lung-cancer-and-hematologic-malignancy-a-comprehensive-analysis-of-clinicopathological-features-and-genetic-abnormalities
#32
JOURNAL ARTICLE
Mengchen Lyu, Lifeng Luo, Ling Zhou, Xiangran Feng, Jin Yang, Ziwei Xu, Xianwen Sun, Zhiyao Bao, Xiaofei Wang, Beili Gao, Yi Xiang
BACKGROUND: The incidence of multiple primary cancers (MPC), especially involving primary lung cancer (PLC) and primary hematologic malignancies (PHM), is rising. This study aims to analyze clinicopathological features, gene abnormalities, and prognostic outcomes in individuals diagnosed with PLC-PHM MPC. METHODS: A retrospective analysis included 89 patients diagnosed with PLC-PHM MPC at the Respiratory or Hematology Departments of Ruijin Hospital from 2003 to 2022 (a total of 842,047 people)...
February 24, 2024: Cancer Cell International
https://read.qxmd.com/read/38397754/oxidative-damage-and-telomere-length-as-markers-of-lung-cancer-development-among-chronic-obstructive-pulmonary-disease-copd-smokers
#33
JOURNAL ARTICLE
Elizabeth Córdoba-Lanús, Luis M Montuenga, Angélica Domínguez-de-Barros, Alexis Oliva, Delia Mayato, Ana Remírez-Sanz, Francisca Gonzalvo, Bartolomé Celli, Javier J Zulueta, Ciro Casanova
Lung cancer (LC) constitutes an important cause of death among patients with Chronic Obstructive Pulmonary Disease (COPD). Both diseases may share pathobiological mechanisms related to oxidative damage and cellular senescence. In this study, the potential value of leucocyte telomere length, a hallmark of aging, and 8-OHdG concentrations, indicative of oxidative DNA damage, as risk biomarkers of LC was evaluated in COPD patients three years prior to LC diagnosis. Relative telomere length measured using qPCR and serum levels of 8-OHdG were determined at the baseline in 99 COPD smokers (33 with LC and 66 age-matched COPD without LC as controls)...
January 26, 2024: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/38395390/elevated-expression-of-complement-factor-i-in-lung-cancer-cells-associates-with-shorter-survival-potentially-via-non-canonical-mechanism
#34
JOURNAL ARTICLE
Anna Felberg, Michał Bieńkowski, Tomasz Stokowy, Kamil Myszczyński, Zuzanna Polakiewicz, Kamila Kitowska, Rafał Sądej, Frida Mohlin, Alicja Kuźniewska, Daria Kowalska, Grzegorz Stasiłojć, Ilse Jongerius, Robbert Spaapen, Miguel Mesa-Guzman, Luis M Montuenga, Anna M Blom, Ruben Pio, Marcin Okrój
While numerous membrane-bound complement inhibitors protect the body's cells from innate immunity's autoaggression, soluble inhibitors like complement factor I (FI) are rarely produced outside the liver. Previously, we reported the expression of FI in non-small cell lung cancer (NSCLC) cell lines. Now, we assessed the content of FI in cancer biopsies from lung cancer patients and associated the results with clinicopathological characteristics and clinical outcomes. Immunohistochemical staining intensity did not correlate with age, smoking status, tumor size, stage, differentiation grade, and T cell infiltrates, but was associated with progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS)...
February 21, 2024: Translational Research: the Journal of Laboratory and Clinical Medicine
https://read.qxmd.com/read/38394494/efficacy-of-immune-checkpoint-inhibitors-in-smarca4-deficient-and-tp53-mutant-undifferentiated-lung-cancer
#35
JOURNAL ARTICLE
Jianxin Chen, Qinhong Zheng, Junhui Wang, Xueli Zhang, Yingguo Lv
The present study was conducted to characterize the clinicopathologic characteristics, immunohistochemical staining results, and immune checkpoint inhibitors (ICIs) efficacy in patients with SMARCA4-deficient/TP53 mutant lung cancer. Patients diagnosed with advanced or metastatic undifferentiated lung cancer harboring SMARCA4-deficient and TP53 mutations, however, without targetable sensitive mutations were retrieved from the electronic medical record system. Descriptive statistics were used to describe the baseline characteristics and clinical features including age, gender, eastern cooperative oncology group performance status, disease stage, smoking status, chief complaint, site of the primary mass, tumor size, gross type, symptoms, local invasion, and metastatic sizes...
February 23, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38391911/cell-free-dna-5-hydroxymethylcytosine-signatures-for-lung-cancer-prognosis
#36
JOURNAL ARTICLE
Jianming Shao, Randall J Olsen, Saro Kasparian, Chuan He, Eric H Bernicker, Zejuan Li
Accurate prognostic markers are essential for guiding effective lung cancer treatment strategies. The level of 5-hydroxymethylcytosine (5hmC) in tissue is independently associated with overall survival (OS) in lung cancer patients. We explored the prognostic value of cell-free DNA (cfDNA) 5hmC through genome-wide analysis of 5hmC in plasma samples from 97 lung cancer patients. In both training and validation sets, we discovered a cfDNA 5hmC signature significantly associated with OS in lung cancer patients...
February 6, 2024: Cells
https://read.qxmd.com/read/38382091/single-cell-and-bulk-rna-sequencing-data-jointly-reveals-vdac2-s-impacts-on-prognosis-and-immune-landscape-of-nsclc
#37
JOURNAL ARTICLE
Ying Ma, Bateer Han, Qin Yu, Nashunbayaer Zha, Zhiyuan Deng, Junguo Liang, Rong Yu
Non-small cell lung cancer (NSCLC) is characterized by stronger metastatic ability and worse prognosis. In NSCLC, hypoxia is a major cause of invasion and metastasis through promoting angiogenesis. In present study, NSCLC cell clusters were extracted from single cell-sequencing dataset GSE131907, which were combined with hypoxia-related genes to group clusters. qRT-PCR and western blot were used to validate the expression of target gene. Nine NSCLC clusters were extracted, which were divided into two hypoxia-related subgroups, C1 and C2...
February 20, 2024: Aging
https://read.qxmd.com/read/38372114/high-expression-of-vta1-is-an-adverse-prognostic-factor-in-lung-adenocarcinoma
#38
JOURNAL ARTICLE
Xingang Sun, Ruixin Wu, Xinjun Guan, Changsheng Dong, Dongze Qiu, Guojie Xia, Shouhan Feng, Jinlong Duan, Lei Zhang
Lung adenocarcinoma (LUAD) is a common pathological type of non-small cell lung cancer; identifying preferable biomarkers has become one of the current challenges. Given that VTA1 has been reported associated with tumor progression in various human solid cancers but rarely reported in LUAD, herein, RNA sequencing data from TCGA and GTEx were obtained for analysis of VTA1 expression and differentially expressed gene (DEG). Furthermore, functional enrichment analysis of VTA1-related DEGs was performed by GO/KEGG, GSEA, immune cell infiltration analysis, and protein-protein interaction (PPI) network...
January 31, 2024: Cellular and Molecular Biology
https://read.qxmd.com/read/38361741/the-efficacy-and-safety-of-treating-acquired-met-resistance-through-combinations-of-parent-and-met-tyrosine-kinase-inhibitors-in-patients-with-metastatic-oncogene-driven-nsclc
#39
JOURNAL ARTICLE
Tejas Patil, Alyse Staley, Yunan Nie, Mandy Sakamoto, Margaret Stalker, James M Jurica, Kenna Koehler, Amanda Cass, Halle Kuykendall, Emily Schmitt, Emma Filar, Evelina Reventaite, Kurt D Davies, Hala Nijmeh, Mary Haag, Benjamin A Yoder, Paul A Bunn, Erin L Schenk, Dara L Aisner, Wade T Iams, Melina E Marmarelis, D Ross Camidge
INTRODUCTION: Acquired MET gene amplification, MET exon 14 skip mutations, or MET fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in patients with lung cancer. The efficacy and safety of combining MET TKIs (such as crizotinib, capmatinib, or tepotinib) with parent TKIs to target acquired MET resistance are not well characterized. METHODS: Multi-institutional retrospective chart review identified 83 patients with metastatic oncogene-driven NSCLC that were separated into the following two pairwise matched cohorts: (1) MET cohort (n = 41)-patients with acquired MET resistance continuing their parent TKI with a MET TKI added or (2) Chemotherapy cohort (n = 42)-patients without any actionable resistance continuing their parent TKI with a platinum-pemetrexed added...
February 2024: JTO clinical and research reports
https://read.qxmd.com/read/38353428/bilateral-diffuse-metastases-in-advanced-lung-adenocarcinoma-harboring-egfr-mutations-was-associated-with-a-favorable-prognosis-to-egfr-tkis
#40
JOURNAL ARTICLE
Zhenbang Gu, Peng Huang, Jiali Zhao, Chen Luo, Lingmin Liao, Anwen Liu, Long Huang
Bilateral diffuse metastatic lung adenocarcinoma (BLDM-LUAD) is a special imaging pattern of lung adenocarcinoma (LUAD). We retrospectively assessed survival outcomes and co-mutation characteristics of BLDM-LUAD patients harboring epidermal growth factor receptor (EGFR) mutations who were treated with EGFR-yrosine kinase inhibitors (TKIs). From May 2016 to May 2021, among 458 patients who submitted samples for next generation sequencing (NGS) detection in 1125 patients with non-small-cell lung cancer (NSCLC), and 44 patients were diagnosed as BLDM-LUAD...
June 1, 2024: International Journal of Cancer. Journal International du Cancer
keyword
keyword
17667
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.